Phaseline

Targets › TNFSF13B

TNFSF13B (Tumor necrosis factor ligand superfamily member 13B): drug programs, companies and trials

8 programs from 8 companies in 27 trials: 14 Phase 2, 5 Phase 4, 4 Phase 3, 4 Phase 1; Immunology, Oncology, Genitourinary; next expected readout Jan 2027.

Cytokine that binds to TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. (UniProt, Q9Y275)

Open in Phaseline: the race on TNFSF13B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tongji HospitalTelitacicept Freeze-dried powder Injection 80mg
TACI-Fc fusion protein targeting BLyS and APRIL
TNFSF13B, TNFSF13Phase 4Lupus or SLEMar 2027
GSKBelimumab
Tumor necrosis factor ligand superfamily member 13B inhibitor
TNFSF13BPhase 4Systemic Lupus Erythematosus; Lung Diseases, Interstitial; Connective Tissue Diseases; Systemic Sclerosis Associated Interstitial Lung Disease …Jun 2027
Vera TherapeuticsAtacicept
Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor
TNFSF13B, TNFSF13Phase 3IgA Nephropathy; IgA Nephropathy (IgAN); pMNSep 2027
Zura BioTibulizumab (ZB-106)
Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor
TNFSF13B, IL17APhase 2Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc)Apr 2027
Beijing Tongren HospitalTaitacept (Telitacicept)
BAFF receptor fusion protein; inhibitor of B-cell activating factor (BAFF) and a prolifera
TNFSF13BPhase 2Anti-N-Methyl-D-Aspartate Receptor EncephalitisJul 2027
Xuzhou Medical UniversityAPRIL-BAFF-Bicephali CAR-T cells
Dual-targeted CAR-T cell therapy against APRIL and BAFF ligands
TNFSF13, TNFSF13BPhase 1Multiple MyelomaJan 2027
Mayo ClinicAutologous BAFFR-targeting CAR T Cells
BAFFR-targeted CAR T cell therapy
TNFSF13BPhase 1B-Cell Non-Hodgkin LymphomaDec 2040
Luminary TherapeuticsLMY-920
BAFF CAR-T cells targeting BAFF ligand
TNFSF13BPhase 1Systemic Lupus Erythematosus–

Conditions

Systemic Lupus Erythematosus (3) Lung Diseases, Interstitial (1) Connective Tissue Diseases (1) Systemic Sclerosis Associated Interstitial Lung Disease (1) Sjogren's Syndrome (1) Lupus Nephritis (1) Lupus Erythematosus, Systemic (1) Primary Immune Thrombocytopenia (ITP) (1) Antiphospholipid Syndrome (APS) (1) Systemic Lupus Erythematosus (SLE) (1) Chronic Lymphoid Leukemia in Relapse (1) Systemic Sclerosis (1)

Modalities

antibody (4), mixed (2), protein or peptide (1)

Companies

GSK (1) Xuzhou Medical University (1) Mayo Clinic (1) Beijing Tongren Hospital (1) Vera Therapeutics (1) Zura Bio (1) Luminary Therapeutics (1) Tongji Hospital (1)

Related targets

TNFSF13 (3) IL17A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.